ecent advances in transdermal drug systems permit continuous delivery of medications to R patients for a variety of indications. The development of such a system for fentanyl (Duragesic, Janssen Pharmaceutica) has greatly expanded the use of systemic fentanyl for patients with chronic pain. Using this device, serum concentrations of fentanyl reach a plateau after approximately 18 h and tend to remain stable thereafter (1) . Few complications have been reported, of which nausea and somnolence are the most common (1,2). We report a case of acute toxic delirium in a patient who used transdermal fentanyl patches for 24 days.
Case Report
A 71-year-old woman with squamous cell carcinoma had undergone a hemimandibulectomy followed by maximal radiation therapy. She lived alone and was stable until 2 wk before admission, when she sought relief of increasing jaw pain. She was given a Duragesic 25-pg/h patch. When her pain persisted the next day, she was switched to a 5 0 -p g h patch and told to increase her dose by 25 pg/h once daily until pain control was achieved. Four days before admission, she again complained of pain despite the use of 125 pg/h of transdermal fentanyl. The next day, she began to hallucinate, and her family described her as having become delusional. Admission was arranged.
On the day of admission, the patient was using two 50-pglh Duragesic patches and one 25-pgA-1 patch. The next day, she was given one tablet of 60-mg sustained-release morphine sulfate. On the third day, she said, "This is some kind of trick." She was confused during the evening, asking for breakfast and trying to get up to go home. Lorazepam (0.5 mg orally) was given at bedtime. On the fourth day, the transdermal fentanyl patches were replaced, and she was also given three doses of 60-mg sustained-release morphine sulfate during the day and an evening dose of lorazepam (0.5 mg). She appeared restless and spent the entire night pacing her room, confused and agitated. On the fifth day, she remained confused, agitated, and paranoid despite four doses of lorazepam (0.5 mg) and two 60-mg morphine tablets during the day. On the sixth day, the same pattern continued, despite the addition of haloperidol (0.5 mg) given by mouth. Serum concentrations of sodium, potassium, magnesium, calcium, vitamin B,,, and folate were normal; the urea nitrogen and creatinine concentrations were 44 and 2.2 mg/dL, respectively. A computed tomography scan of the head was essentially normal. She remained confused and agitated on hospital days 7-9. On the ninth day, psychiatric consultation was requested after full-time sitters were required, despite daily doses of haloperidol (up to 9 mg on day 9). The transdermal fentanyl patches, 100 and 25 pgh, had been replaced on day 7.
Psychiatric assessment on day 9 revealed an elderly, cachectic woman standing beside her bed, picking aimlessly at the bedclothes. She had been incontinent of stool. Pupils were pinpoint. She was able to give only one-or two-word responses. She was oriented to the year but not to month, date, or place. She was able to name her daughter and sister (they were present in the room) but could not describe their relationships correctly. She was uncooperative with further mental status examination. Her affect was flat, and she was in no obvious pain. The psychiatrist diagnosed toxic delirium.
On the tenth hospital day, the transdermal fentanyl patches were removed, and intravenous morphine at 4 mg/h was begun. The next day the patient was dozing comfortably, able to ambulate with assistance to the toilet, and began to take fluids by mouth. She was no longer combative and denied experiencing pain. Her mental state improved so that sitters and antipsychotic medications were discontinued. She was maintained on modest doses of intravenous and oral morphine and required only general supportive care until her discharge to an extended care facility on hospital day 28. During this time, she was alert and oriented, reading books, listening to the radio, and visiting with family members.
Discussion
Fentanyl is a phenylpiperidine derivative, structurally related to meperidine. Like meperidine, it can be metabolized by N-demethylation, producing norfentanyl, which is structurally similar to normeperidine (Figure 1 ). Norfentanyl may be the principal metabolic degradation product of fentanyl in humans (3-5). It is excreted by the kidney and can be detected in the urine 72 h after a single intravenous dose of fentanyl (3). Animal studies suggest that norfentanyl has less analgesic potency than fentanyl (4). No detailed pharmacokinetic data or information concerning its physiologic effects in humans appears in the literature. Normeperidine can accumulate in the serum and cause a variety of adverse effects in patients taking repeated doses of meperidine (6-8). Its serum half-life of 15-30 h is prolonged in patients with diminished renal function (6,7). Normeperidine appears to have antianalgesic properties and has been associated with negative mood alterations. It can cause a variety of central nervous system excitation effects, including tremors, myoclonus, and grand ma1 seizures (6,8) . These adverse effects cannot be reversed with naloxone (6).
We suspect that norfentanyl began to accumulate in this patient's serum, perhaps accelerated by her advanced age, general debility, and renal insufficiency. The effects of age on fentanyl pharmacokinetics remain unclear. Singleton et al. (9) found that the clearance and elimination half-life of intravenous fentanyl in healthy elderly persons was the same as in a younger group. Two reports suggest that the elimination half-life of fentanyl in healthy adults after transcutaneous administration for 1 day is 16-21 h (10,ll). Esteve et al. (12) confirmed this result in a group aged 30-65 yr but found that older patients (78-88 yr; n = 6 ) had an elimination half-life of 43 h. The effect of age, if any, on the clearance of norfentanyl is unknown. The potential actions of norfentanyl, toxic or otherwise, remain speculative; however, its structural similarity to normeperidine raises the possibility that it has similar physiologic effects. If so, it may have been responsible for the excitation and narcotic resistance demonstrated by our patient.
There are a number of other potential causes for this patient's delirium. Persons receiving potent opiates may experience a variety of subjective effects, including hallucinations and delirium. Such paradoxical reactions usually occur shortly after the opiate is administered and can be reversed with naloxone. A literature search revealed a single case report of acute delirium that occurred after intravenous administration of fentanyl (100 pg) (13). This patient's mental status returned to normal shortly after she received naloxone. Another report describes a case in which acute delirium followed general anesthesia during which the patient also received droperidol and epidural fentanyl. In this instance, no naloxone was administered, and the patient recovered gradually over 2 days (14) . We also cannot exclude with certainty the possibility of an adverse reaction to one of her other medicines as a cause of her altered sensorium. However, all of these, except the transdermal fentanyl patch, were continued after the resolution of her delirium. The list of potential side effects of Duragesic noted in the package insert includes hallucinations, agitation, abnormal thinking, and paranoid reaction. However, the manufacturer was unable to provide any specific case histories to support this information (I.H. White, personal communication), and no published reports link transdermally administered fentanyl to these side effects.
Large doses of opiates may cause hypoventila tion and hypoxemia, although this usually coincides with clinically obvious sedation. Hypoxemia occasionally presents as confusion. Neither arterial blood gases nor hemoglobin saturation was measured directly in this case, but the patient had normal pulmonary function and remained alert and active, even agitated, throughout the period of her confusion. She continued to complain of pain before her admission, despite the use of transdermal fentanyl (125 @h). The addition of up to 120 mg/day of oral morphine did not fully relieve her discomfort. This represents an opiate dose equivalent to more than 14 mg/h of morphine. In the subsequent absence of fentanyl, she remained comfortable while receiving only intravenous morphine at 4-5 mg/h. The absence of effective pain control and the clinical picture of an active patient suggest that opiate overdose with respiratory depression was not the major issue. It is unfortunate that this impression was not confirmed by a blood gas measurement.
In summary, we present a patient with renal insufficiency who experienced poor pain control and developed an acute toxic delirium while receiving transdermal fentanyl in doses of up to 125 p g h One day after the fentanyl patch was removed, her pain could be controlled with intravenous morphine at 4-5 mgih, and her mental status abnormalities resolved without specific treatment. We suspect that accumulation of norfentanyl in her serum caused her narcotic resistance and delirium.
